Future Market Insights (FMI), a leading market research firm, has released a comprehensive analysis projecting a promising future for the Global Injectable Drugs Industry. The forecast indicates a robust Compound Annual Growth Rate (CAGR) of 5.8% throughout the assessment period, culminating in a staggering valuation of US$937.0 billion by 2032.
The significant growth anticipated in the Injectable Drugs Industry is attributed to continuous advancements in technologies designed to optimize devices for clinical conditions, whether chronic or acute. The healthcare sector, a bastion of innovation, has experienced remarkable progress in clinical solutions. The introduction of minimally invasive treatments and the evolution of diagnostic and management practices for high-risk patients have been pivotal contributors to the industry’s upward trajectory.
Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-15073
Demand for related treatments is increasing, as people are now more aware of the right treatment options, doctor-guided plans, and precautionary measures to consider for serious clinical conditions.
Key players in the Global Injectable Drugs Industry are actively seeking to gain approvals from regulatory bodies and develop products across the continuum of care in severe case recovery. Furthermore, the FDA is expected to approve new devices related to advanced injectable drugs and their administration, over the coming years.
“Increasing incidence of infectious diseases, oncological diseases, cardiac disorders and device innovation are prompting healthcare providers to incorporate new treatment regimens for improved patient outcome,” says an FMI analyst.
Global Injectable Drugs Industry Key Takeaways:
- By product, monoclonal antibodies held the largest share of 5% in the global market in 2021.
- Based on application, infectious diseases segment held the largest share of 4% in the global market in 2021, with the segment expected to expand at 5.7% CAGR over the forecast period.
- In terms of molecule, large molecule segment held the largest share of 8% in the global market in 2021.
- By route of administration, sales in the intravenous (IV) segment are expected to increase at a 3% CAGR over the assessment period.
- Based on distribution channel, the hospital pharmacies segment was valued at US$ 231.0 Bn in 2021.
- North America held the largest share of 5% in the global injectable drugs treatment market in 2021, owing to the growing government investments in healthcare and R&D activities.
Global Injectable Drugs Industry Competitive Landscape
Product launches and collaborations with suppliers that have a strong position and are popular in the market are some of the key strategies of the market players operating in the Global Injectable Drugs Industry. For instance:
- Merck and Gilead Sciences, Inc. (Gilead) signed an agreement in March 2021 to collaborate on the development and commercialization of long-acting HIV treatments that combine Merck’s investigational nucleoside reverse transcriptase translocation inhibitor islatravir and Gilead’s investigational capsid inhibitor lenacapavir.
- In March 2022, Sanofi IGM Biosciences, Inc. today announced the signing of an exclusive worldwide collaboration agreement to create, develop, manufacture, and commercialize IgM antibody agonists against three oncology targets and three immunology/inflammation targets. Engineered IgM antibodies represent a new class of potential therapeutics that combine the multi-valency of IgM antibodies possessing 10 binding sites compared to conventional IgG antibodies having only 2 target binding sites.
- In February 2022, Novartis India Limited extends access to its medicines in India by signing exclusive sales and distribution agreement with Dr. Reddy’s Laboratories
Request Methodology Now!
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-15073
What Does the Report Cover?
Future Market Insights offers a unique perspective and actionable insights on the injectable drugs market in its latest study, presenting a historical demand assessment of 2014 – 2021 and projections for 2022 – 2032.
The research study is based on the product – (monoclonal antibodies, immunoglobulin, cytokines, insulin, peptide hormones, blood factors, peptide antibiotics, vaccines, small molecule antibiotics, chemotherapy agents, and others), by application (oncology, infectious diseases, diabetes, blood disorders, hormonal disorders, musculoskeletal disorders, CNS diseases, pain management, and cardiovascular diseases), by molecule type (small molecules and large molecules), by route of administration (intravenous (IV), intramuscular (IM), and subcutaneous (SC)), by distribution channel (hospital pharmacies, retail pharmacies, drug stores, and online pharmacies), across seven key regions of the world.
Global Injectable Drugs Industry Key Players:
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Sanofi S.A.
- Sun Pharmaceutical Industries Ltd.
- AstraZeneca Plc
- Merck & Co., Inc.
- Viatris + Mylan N.V
- Cipla Inc.
- Dr. Reddy’s Laboratories Ltd.
- Samsung Biologics
- Abbott Laboratories
- Amgen Incorporated
- Baxter International Incorporated
- Becton Dickinson and Company
- Bristol-Myers Squibb Company
- GlaxoSmithKline Plc
- Roche Holding Limited
Click Here To Buy Your Full Report
https://www.futuremarketinsights.com/checkout/15073
Key Segments Covered in Global Injectable Drugs Industry Research
By Product:
- Monoclonal Antibodies
- Immunoglobulin
- Cytokines
- Insulin
- Peptide Hormones
- Blood Factors
- Peptide Antibiotics
- Vaccines
- Small Molecule Antibiotics
- Chemotherapy Agents
- Others
By Application:
- Oncology
- Infectious Diseases
- Diabetes
- Blood disorders
- Hormonal Disorders
- Musculoskeletal Disorders
- CNS Diseases
- Pain Management
- Cardiovascular Diseases
By Molecule Type:
- Small Molecules
- Large Molecules
By Route of Administration:
- Intravenous (IV)
- Intramuscular (IM)
- Subcutaneous (SC)
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
